IMRT 2018

… Benefit of Androgen Deprivation - EORTC Trial 22991

Phase 3 trial showing benefit

Six months of concomitant and adjuvant AD

Improves biochemical and clinical DFS of intermediate and high- risk cT1b-c to cT2a

13% gain in 5 year PSA control

Bolla 2016